Clinical Trial Detail

NCT ID NCT00876993
Title Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors All Children’s Hospital Johns Hopkins Medicine
Indications

medulloblastoma

pediatric ependymoma

malignant glioma

Therapies

Bevacizumab + Irinotecan + Temozolomide

Age Groups: child

No variant requirements are available.